Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

BMO Capital Upgrades Replimune Group to Market Perform, Raises Price Target to $11

Author: Benzinga Newsdesk | November 03, 2025 05:37am
BMO Capital analyst Evan David Seigerman upgrades Replimune Group (NASDAQ:REPL) from Underperform to Market Perform and raises the price target from $2 to $11.

Posted In: REPL


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist